Revised SPC: Yervoy (ipilimumab) 5 mg/ml concentrate for solution for infusion

SPC revised with licence extension to include use in combination with nivolumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.

Source:

electronic Medicines compendium